Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD
Public ClinicalTrials.gov record NCT03282123. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Multi-Site Phase 2 Study of the Safety and Effect of Manualized MDMA-Assisted Therapy for the Treatment of Severe Posttraumatic Stress Disorder
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective in people diagnosed with at least severe PTSD. The main question it aims to answer is: Do three open-label sessions of MDMA-assisted therapy reduce PTSD symptoms? Participants will receive three non-drug preparatory sessions followed by three sessions of MDMA-assisted therapy. Each MDMA-assisted therapy session is followed by three non-drug integrative therapy sessions.
Study identification
- NCT ID
- NCT03282123
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 38 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 16, 2017 (Actual)
- Primary completion
- Aug 10, 2019 (Actual)
- Completion
- Aug 10, 2019 (Actual)
- Last update posted
- Jun 5, 2025
2017 – 2019
United States locations
- U.S. sites
- 12
- U.S. states
- 8
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| New School Research LLC | North Hollywood | California | 91601 | — |
| San Francisco Insight and Integration Center | San Francisco | California | 94114 | — |
| University of California San Francisco | San Francisco | California | 94122 | — |
| Aguazul-Blue Water Inc. | Boulder | Colorado | 80302 | — |
| Wholeness Center | Fort Collins | Colorado | 80525 | — |
| University of Connecticut | Farmington | Connecticut | 06030 | — |
| Ray Worthy Psychiatry LLC | New Orleans | Louisiana | 70123 | — |
| Trauma Research Foundation | Brookline | Massachusetts | 02446 | — |
| New York University | New York | New York | 10016 | — |
| Affective Care | New York | New York | 10024 | — |
| Zen Therapeutic Solutions, LLC | Mt. Pleasant | South Carolina | 29464 | — |
| University of Wisconsin at Madison | Madison | Wisconsin | 53705 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03282123, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 5, 2025 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03282123 live on ClinicalTrials.gov.